News

Cofounder, president and COO of HealthReveal Lori Evans Bernstein offers tips for women founders. 

The firm also announced a deal with a Fortune 200 company to launch gestational diabetes product in the US.

The technology includes one-time use sensors and can switch between blind and unblinded mode. 

CNBC reports that the digital primary care provider has hired banks leading up to an IPO. 

The new funding brings the company's total Series B to $55 million. 

The item could measure blood pressure, respiration rate and ECG signals. 

Also: OptimizeRx delivers messaging through NewCrop's electronic prescription software; Novo Nordisk expands collaboration with Noom following strong pilot; Livongo signs its biggest payer yet.

The independent investigation suggests that wirelessly observed therapies using Proteus' system could be considered equivalent to in-person medication adherence programs, but much better received by patients taking oral medications.

The deal is expected to add 45,000 new Livongo members by 2021. 

This latest round was led by LBO France with participation from Kurma Diagnostics, Paris Saclay, Idinvest Partners, Seventure and SOSV.